CROI 2017 Program and Information

Program and Agenda

570 VIRAL KINETICS PREDICT RESPONSE TO ALL-ORAL THERAPY AGAINST HCV GENOTYPE 3 INFECTION Juan A. Pineda 1 , Luis E. Morano-Amado 2 , Rafael Granados 3 , Juan Macías 4 , Francisco Téllez 5 , Miguel García-Deltoro 6 , Maria J. Rios-Villegas 7 , Antonio Collado 8 , Karin Neukam 4 , for the GEHEP-MONO/ HEPAVIR-DAA, RIS-HEP07 and RIS-HEP13 Study Groups 1 Hosp Univ de Valme, Seville, Spain, 2 Hosp Univ Alvaro Cunqueiro, Vigo, Spain, 3 Hosp Univ de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain, 4 Hosp Univ de Valme, Sevilla, Spain, 5 Hosp de La Línea, La Línea de la Concepción, Spain, 6 Hosp General de Valencia, Valencia, Spain, 7 Hosp Univ Virgen Macarena, Sevilla, Spain, 8 Hosp Univ Torrecárdenas, Almeria, Spain 571 ALL ORAL DAA THERAPY INHCV GENOTYPE 4 INFECTIONWITH ANDWITHOUT HIV COINFECTION Juan A. Pineda 1 , Luis E. Morano-Amado 2 , Francisco Téllez 3 , Blanca Figueruela López 4 , Marcial Delgado-Fernández 5 , Antonio Rivero-Juárez 6 , Dolores Merino 7 , Montserrat Pérez-Pérez 8 , Karin Neukam 1 , for the GEHEP- MONO/ HEPAVIR-DAA, RIS-HEP07 and RIS-HEP13 Study Groups 1 Hosp Univ de Valme, Sevilla, Spain, 2 Hosp Univ Alvaro Cunqueiro, Vigo, Spain, 3 Hosp de La Línea, La Línea de la Concepción, Spain, 4 Hosp Univ de Valme, Seville, Spain, 5 Hosp Regional Univ de Málaga, Málaga, Spain, 6 Hosp Univ Reina Sofía, Córdoba, Spain, 7 Complejo Hospario Univ de Huelva, Huelva, Spain, 8 Hosp La Línea, AGS Campo de Gibraltar, La Linea de la Concepcion, Spain 572 EFFECTIVENESS OF ALL-ORAL DAAs FOR HCV GENOTYPE 3 IN HIV/HCV-COINFECTED PATIENTS Juan González-García 1 , Ana Moreno 2 , Encarnnnacion Cruz 3 , Lourdes Domínguez-Domínguez 4 , Victoria Moreno 1 , Jorge Vergas 5 , Jose Sanz 6 , Laura Benitez 7 , Beatriz Álvarez 8 , Juan Berenguer 9 1 Hosp Univ La Paz, Madrid, Spain, 2 Hosp Ramon y Cajal, Madrid, Spain, 3 Subdireccion General de Farmacia, Madrid, Spain, 4 Hosp Univ 12 de Octubre, Madrid, Spain, 5 Hosp Clinico San Carlos, Madrid, Spain, 6 Hosp Príncipe de Asturias, Alcalá de Henares (Madrid), Spain, 7 Clinica Puerta de Hierro, Majadahonda (Madrid), Spain, 8 Hosp Univ Fundación Jiménez Díaz, Madrid, Spain, 9 Hosp General Univ Gregorio Marañón, Madrid, Spain 573 SOFOSBUVIR/LEDIPASVIR AS CHOLESTEROL-INCREASE RISK FACTOR INHIV SUBJECTS

Poster Sessions • Wednesday

Mario Frías , Antonio Rivero-Juárez, Francisca Cuenca-Lopez, Angela Camacho-Espejo, Diego Rodriguez-Cano, Pedro Lopez-Lopez, Teresa Brieva, Antonio Rivero Hosp Univ Reina Sofia, Cordoba, Spain

574 LIPID LEVELS AND THE RISK OF ACUTEMYOCARDIAL INFARCTION AMONG HCV+AND HCV- PERSONS

Adeel A. Butt 1 , Peng Yan 2 , Kara Chew 3 , Judith S. Currier 3 , Kathleen Corey 4 , Raymond Chung 4 , Abdul-Badi Abou-Samra 5 , Javed Butler 6 , Matthew Freiberg 7 , for the ERCHIVES 1 Hamad Hlthcare Quality Inst and Hamad Med Corporation, Doha, Qatar, 2 VA Pittsburgh Hlthcare System, Pittsburgh, PA, USA, 3 Univ of California Los Angeles, Los Angeles, CA, USA, 4 Massachusetts General Hosp, Boston, USA, 5 Hamad Medica Corporation, Doha, Qatar, 6 SUNY Stonybrook, Stony Brook, NY, USA, 7 Vanderbilt Univ Sch of Med, Nashville, TN, USA 575 EFFECT OF INTERFERON-FREE TREATMENT ON LIPID AND GLUCOSEMETABOLISM INHEPATITIS C Elisa Biliotti , Donatella Palazzo, Marco Serani, Rozenn Esvan, Paola Maida, Paola Perinelli, Martina Spaziante, Alessandro Maria Silvestri,

Lorenzo Volpicelli, Gloria Taliani Sapienza Univ of Rome, Rome, Italy

CROI 2017 142